ArticleTrials2025
Randomized controlled trial of effects of metformin in NAFLD patients with newly diagnosed type 2 diabetes treated with an intensive lifestyle: a study protocol.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GLUT5-Driven Gut-Liver Axis Injury Mediating Olanzapine-Induced NAFLD and Dapagliflozin Intervention.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common chronic diseases. The coexistence of NAFLD and diabetes accelerates the progression of both and tends to induce bad prognosis. To date, lifestyle modification has been suggested as the first-line treatment for NAFLD patients. Some studies indicated that lifestyle modification could normalize glucose levels in newly diagnosed T2DM, but many individuals do not reach glycemic targets in practice using lifestyle modification alone. Considering the tight link between NAFLD and T2DM, metformin, a widely used drug in diabetic patients with a good safety profile, may be a possible treatment or control of NAFLD progression. There is no therapeutic consensus for the treatment of NAFLD patients with diabetes. Therefore, it is essential to elucidate the beneficial effects of lifestyle modification combined with metformin on glucose-lipid metabolism in the NAFLD population with newly diagnosed T2DM.
methodsParticipants will be recruited in this single-center, randomized clinical trial through telephone interview. All participants will be assigned randomly at a 1:1:1 ratio to three groups and treated with lifestyle modification including calorie-restricted dietary and exercise therapy, 500-2000 mg/day metformin, or treated with both lifestyle modification and 500-2000 mg/day metformin (the co-intervention group) for 12 weeks. The primary outcomes are changes in glycemic control and severity of fatty liver from baseline to 12 weeks of follow-up. DISCUSSION: This trial is designed to clarify whether lifestyle intervention combined with metformin has synergistic effects on glycemic control, attenuating the progression of NAFLD in NAFLD patients with newly diagnosed T2DM.
trial registrationChiCTR2300072031. Registered on 31 May 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.